USPTO serial 79312395
HER2DX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 29, 2022
- Examiner
- HAN, DAWN L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HER2DX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Donna A. Tobin
Donna A. Tobin Royer Cooper Cohen Braunfeld LLP1120 Avenue of the Americas4th FloorNew York, NY 10036Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations for scientific use; reagents for research purposes; reagents for medical research purposes; diagnostic reagents for scientific use or for research use; reagents for scientific use or for research use in the field of cancer; diagnostic reagents for clinical or medical laboratory use in the field of in vitro in biochemistry, clinical chemistry and microbiology | ACTIVE | — |
| 005 | Products for medical diagnostics, namely, medical diagnostic reagents, medical diagnostic assays for testing body fluids and tissue, and specimen collection kits comprised of swabs for medical purposes and plastic bags for transmitting medical specimens, all for use in cancer detection; diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; medical reagents for clinical use; medical diagnostic reagents for the analysis of body fluids and tissue; diagnostic reagents for use in diagnostic testing for medical purposes; diagnostic biomarker reagents for cancer diagnosis, prognosis and treatment for medical purposes; medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of body fluids and tissue, and diagnostic reagents for medical use, all for cancer diagnosis, prognosis and treatment; pharmaceutical products for the treatment of cancer; biological preparations for cancer treatment; biopharmaceutical preparations for cancer treatment; pharmaceutical preparations for the treatment of cancer for oncological use; biological reagents, namely, clinical medical reagents; diagnostic reagent kits consisting primarily of diagnostic reagents for medical use, in the field of cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by REVEAL GENOMICS S.L.
- Other trademarks owned by REVEAL GENOMICS S.L.
- Other trademarks owned by REVEAL GENOMICS S.L.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named HER2DX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 12, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 17, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 17, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 28, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 29, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 29, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 27, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 9, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 9, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 3, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 13, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 13, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 7, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 7, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 24, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 4, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 15, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 15, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 15, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 15, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 14, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 14, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 14, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 14, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 3, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 26, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 26, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 3, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 3, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 3, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 2, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 24, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 11, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 7, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 3, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |